A team of researchers from Henan University of Science and Technology have introduced a novel method for improving drug testing for esophageal cancer (EC) using advanced three-dimensional (3D) cell culture technology. The ...
Jul 22, 2024
0
0
A new compound developed by researchers at MUSC Hollings Cancer Center shows promise in overcoming chemotherapy resistance in triple-negative breast cancer—and could potentially be applied to fibrotic conditions like liver ...
Jul 22, 2024
0
29
A medication used to treat diabetic neuropathy may make chemotherapy treatments more effective for patients with lung cancer, according to new findings from the University of Missouri School of Medicine published in Clinical ...
Jul 17, 2024
0
4
In an editorial, published in Oncoscience titled, "Entering the golden age for antibody-drug conjugates in gynecologic cancer," researchers Michelle Greenman, Blair McNamara, Levent Mutlu, and Alessandro D. Santin from Yale ...
Jul 15, 2024
0
0
Cancer's resistance to chemotherapy could be reversed by targeting lactate—the product that builds up as cancer cells convert nutrients to energy, according to new research published in Nature.
Jul 4, 2024
0
31
An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and ...
Jun 18, 2024
0
1
Developing chemotherapy drugs against breast cancer is costly, slow, and often inefficient, with more than 95% of screened drug candidates failing in patient trials. A new technique for 3D cell culturing, developed by researchers ...
Jun 11, 2024
0
1
A new perspective paper explores the current state and future directions of precision medicine in colorectal cancer (CRC). It outlines advancements in molecular testing and their implications for targeted and immunological ...
May 2, 2024
0
0
When cancer patients undergo chemotherapy, the dose of most drugs is calculated based on the patient's body surface area. This is estimated by plugging the patient's height and weight into an equation, dating to 1916, that ...
Apr 24, 2024
0
19
The U.S. Food and Drug Administration has approved Genentech's Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Apr 23, 2024
0
0
